Skip to main content
SpringerLink
Log in
Book cover

Manual on Assisted Reproduction pp 154–169Cite as

Ovarian Hyperstimulation Syndrome

  • Chapter

  • 137 Accesses

Abstract

Almost all complications of gonadotropin treatment are due essentially to ovarian stimulation, multiple follicular development and luteinization, or ovulation of numerous follicles. The main complications are: (a) high incidence of multiple pregnancy which may result in serious gestational and perinatal complications such as prematurity, pathological lies, and presentations and high incidence of cesarean sections, (b) ovarian hyperstimulation syndrome (OHSS).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Rabau E, Serr DM, David A, Mashiach S, Lunenfeld B. Human menopausal gonadotropins for anovulation and sterility. Am J Obstet Gynecol 96: 92, 1967

    Google Scholar 

  2. World Health Organization: Agents stimulating gonadal function in human. WHO Technical Report Series no 514, 1973

    Google Scholar 

  3. Lunenfeld B, Insler V, Glezerman M. Diagnosis and treatment of functional infertility, 3rd edn. Blackwell, Berlin, p 98, 1993

    Google Scholar 

  4. Tulandi T, McInnes RA, Arronet GH. Ovarian hyperstimulation following ovulation induction with human menopausal gonadotropin. Int J Fertil 29: 113, 1984

    PubMed  CAS  Google Scholar 

  5. Hazout A, Belaisch-Allart J. Progres en gynecologie. J Buvat & J Bringer (eds). Doin Publishers, Paris 1986

    Google Scholar 

  6. Yan Zh, Weich HA, Bernart W, Breckwoldt M, Neulen J. Vascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulosa cells in vitro. J Clin Endocrinol Metab 77: 1723 - 1725, 1993

    Article  PubMed  CAS  Google Scholar 

  7. McLure N, Healy DL, Rogers PA, Sullivan J, Beaton L, Haning RV, Connoly DT, Robertson DM. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 344: 235 - 236, 1994

    Article  Google Scholar 

  8. Shweiki D, Itin A, Neufeld G, Gitay-Goren H, Keshet E. Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonallyregulatedangiogenesis. J Clin Invest 91: 2235 - 2243, 1993

    Article  PubMed  CAS  Google Scholar 

  9. Polishuk WZ, Schenker JG. Ovarian overstimulation syndrome. Fertil Steril 20: 443, 1969

    PubMed  CAS  Google Scholar 

  10. Schenker JG, Schumert Z, Shifrin A, Spitz I. Steroid pattern in experimental hyperstimulation syndrome and the response to indomethacin. Presented at the Second International Congress of Human Reproduction, Tel Aviv, October 1977

    Google Scholar 

  11. Schenker JG, Polishuk WZ. The role of prostaglandins in ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod 6: 47, 1976

    Article  CAS  Google Scholar 

  12. Pride SM, Yuen BH, Young SM, Leung PCS. Relationship of gonadotropin releasing hormone, danazol and prostaglandin blockade to ovarian enlargement and sacites formation or the ovarian hyperstimulation syndrome in the rabbit. Am J Obstet Gynecol 154: 1155, 1986

    PubMed  CAS  Google Scholar 

  13. Davis JS. Hormonal control of plasma and erythrocyte volume of rat uterus. Am J Physiol 199: 841, 1960

    PubMed  CAS  Google Scholar 

  14. Cecil HC, Hannun JA Jr, Bitman J. Quantitative characterization of uterine vascular permeability changes with estrogen. Am J Physiol 211: 1099, 1966

    PubMed  CAS  Google Scholar 

  15. Schenker JG, Polishuk WZ. An experimental model of ovarian hyperstimulation syndrome. In: Tischer M, Pilch J (eds) Proceedings of the International Congress on Animal Reproduction, vol 4. Drukarnia Naukowa, Cracow, p 635, 1976

    Google Scholar 

  16. Engel J, Jewelewicz R, Dyrenfurth I, Speroff L, VandeWiele RL. Ovarian hyper-stimulation syndrome. Report of a case with notes on pathogenesis and treatment. Am J Obstet Gynecol 112: 1052, 1972

    PubMed  CAS  Google Scholar 

  17. Sims EA. Renal function in normal pregnancy. Clin Obstet Gynecol 11: 961, 1967

    Google Scholar 

  18. Mudge GH, Welt LG. Agents affecting volume and composition of body Huis. In: Goodman LS, Gilman A (eds) The pharmacological basis of therapeutics, 5th edn. Macmillan, New York, pp 733 - 781, 1975

    Google Scholar 

  19. Friedlander MA, Loret-de-Mola JR, Goldfarb JM. Elevated levels of interleukin-6 in ascites and serum from women with ovarian hyperstimulation syndrome. Fertil Steril 60: 826 - 833, 1993

    PubMed  CAS  Google Scholar 

  20. Balasch J, Arroyo V, Carmona F, Llach J, Jimenez W, Pare JC, Vanrell JA. Severe ovarian hyperstimulation syndrome: role of peripheral vasodilation. Fertil Steril 56: 1077 - 1083, 1991

    PubMed  CAS  Google Scholar 

  21. Ong AC, Eisen V, Rennie DP, Homburg R, Lachelin GC, Jacobs HS, Slater JD. The pathogenesis of the ovarian hyperstimulation syndrome (OHS): a possible role for ovarian renin. Clin Endocrinol (Oxf) 34: 43 - 49, 1991

    Article  CAS  Google Scholar 

  22. Navot D, Margalioth EJ, Laufer N, Birkenfeld A, Relou A, Rosier A, Schenker JG. Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome. Fertil Steril 48: 57 - 61, 1987

    PubMed  CAS  Google Scholar 

  23. Dirks JH, Cirksena WJ, Berliner RW. Micropuncture study of the effect of various diuretics on sodium reabsorption by the proximal tubules of the dog. J Clin Invest 45: 1875 - 1878, 1966

    Article  PubMed  CAS  Google Scholar 

  24. Berliner RW, Kennedy TJJ, Hilton JG. Renal clearance of ferranocyanide in dog. Am J Physiol 160: 348 - 353, 1950

    Google Scholar 

  25. Landau RL, Lugibihl K. Inhibition of the sodium-retaining influence of aldosterone by progesterone. J Clin Endocrinol Metab 18: 1237 - 1242, 1958

    Article  PubMed  CAS  Google Scholar 

  26. Moses M, Bogowsky H, Anteby E, Lunenfeld B, Rabau E, Serr D, David A, Salomy M. Thromboembolic phenomena after ovarian stimulation with human menopausal gonadotrophins. Lancet 2: 1213 - 1215, 1965

    Article  Google Scholar 

  27. Phillips LL, Glanstone W, VandeWiele R. Studies of the coagulation and fibrinolytic systems in hyperstimulation syndrome after administration of human gonadotrophins. J Reprod Med 14: 138, 1975

    PubMed  CAS  Google Scholar 

  28. Schenker JG, Weinstein D. Ovarian hyperstimulation syndrome: a current survey. Fertil Steril 30: 255, 1978

    PubMed  CAS  Google Scholar 

  29. Haning RV Jr, Strawn EY, Nolten WE. Pathophysiology of the ovarian hyper-stimulation syndrome. Obstet Gynecol 66: 220, 1985

    PubMed  Google Scholar 

  30. Gonen Y, Balakier H, Powell W, Casper RF. Use of gonadotropin releasing hormone agonist to trigger follicular maturation for in vitro fertilization. J Clin Endocrinol Metab 71: 918 - 922, 1990

    Article  PubMed  CAS  Google Scholar 

  31. Emperaire JC, Ruffle A. Triggering ovulation with endogenous luteinizing hormone may prevent the ovarian hyperstimulation syndrome. Hum Reprod 6: 506 - 510, 1991

    PubMed  CAS  Google Scholar 

  32. Itskovitz J, Boldes R, Levron J, Erlik Y, Kahana L, Brandes JM. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil Steril 56: 213 - 220, 1991

    PubMed  CAS  Google Scholar 

  33. Corson SL, Batzer FR, Gocial B, Meislin G. The luteal phase after ovulation induction with human menopausal gonadotropin and one versus two doses of gonadotropin-releasing hormone agonist. Fertil Steril 59: 1251 - 1256, 1993

    PubMed  CAS  Google Scholar 

  34. van der Meer S, Gerris J, Joostens M, Tas B. Triggering of ovulation using a gonadotropin-releasing hormone agonis does not prevent ovarian hypperstimulation syndrome. Hum Reprod 8: 1628 - 1631, 1993

    PubMed  Google Scholar 

  35. Lanzone A, Fulghesu AM, Villa P, Guida C, Guido M, Nicoletti MC, Caruso A, Mancuso S. Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin as a trigger of ovulation in polycystic ovarian disease gonadotropin hyperstimulated cycles. Fertil Steril 62: 35 - 41, 1994

    PubMed  CAS  Google Scholar 

  36. Hsueh AJ, Liu YX, Cajander S, Peng XR, Dahl K, Kristensen P, Ny T. Gonadotropinreleasing hormone induces povulation in hypophysectomized rats: studies on ovarian tissue-type plasminogen activator activity, messenger ribonucleic acid content and cellular localization. Endocrinology 122: 1486 - 1495, 1988

    Article  PubMed  CAS  Google Scholar 

  37. Tal J, Paz B, Samberg I, Lazarov M, Sharf M. Ultrasonographic and clinical correlates of menotropin versus sequential clomiphene citrate: menotropin therapy for induction of ovulation. Fertil Steril 44: 342, 1985

    PubMed  CAS  Google Scholar 

  38. Blankstein J, Shalef J, Saadon T, Kukia E, Rabinovich J, Pariente C, Lunenfeld B, Serr D, Mashiach S. Prediction OHSS by preovulatory follicles. Fertil Steril 47: 4, 1987

    Google Scholar 

  39. Tan SL, Balen A, Hussein E, Campbell S, Jacobs HS. The administration of glucocorticosteroids for the prevention of ovarian hyperstimulation syndrome in in-vitro fertilization: a prospective randomized study. Fertil Steril 58: 378 - 383, 1992

    PubMed  CAS  Google Scholar 

  40. Asch RH, Ivery G, Goldman M, Frederick JL, Stone SC, Balmaceda JP. The role of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome. Hum Reprod 8: 1015 - 1020, 1993

    PubMed  CAS  Google Scholar 

  41. Shoham Z, Weissman A, Barash A, Borenstein R, Schachter M, Insler V. Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilizatioon program: a prospective, randomized, placebo-controlled study. Fertil Steril 62: 137 - 142, 1994

    PubMed  CAS  Google Scholar 

  42. Fischer R, Baukohl V, Naether O, Nuckel M, Human serum albumin and 10% hydroxyethyl starch infusion as a preventive treatment of severe ovarian hyper-stimulation syndrome. Hum Reprod 9: 123 - 124, 1994

    Google Scholar 

  43. Insler V, Lunenfeld B. Diagnosis und Therapie endokriner Fertilitaetsstoerungen der Frau. Berlin, Grosse Verlag 1983, p 96

    Google Scholar 

  44. Thaler I, Yoffe N, Kaftory JK, Brandes JM. Treatment of ovarian hyperstimulation syndrome: the physiologic basis for a modified approach. Fertil Steril 36: 110, 1981

    PubMed  CAS  Google Scholar 

  45. Schenker JG, Weinstein D. Ovarian hyperstimulation syndrome: a current survey. Fert Steril 30: 255, 1978

    CAS  Google Scholar 

  46. Borenstein R, Elhalal U, Lunenfeld B, Schwartz ZS. Severe ovarian hyperstimulation syndrome: a re-evaluated therapeutic approach. Fertil Steril 51: 791 - 795, 1989

    PubMed  CAS  Google Scholar 

  47. Aboulghar MA, Mansour RT, Serour GI, Sattar MA, Amin YM, Elattar I. Management of severe ovarian hyperstimulation syndrome by ascitic fluid aspiration and intensive intravenous fluid therapy. Obstet Gynecol 81: 108 - 111, 1993

    PubMed  CAS  Google Scholar 

  48. Aboulghar MA, Mansour RT, Serour GI, Riad R, Ramzi AM. Autotransfusion of the ascitic fluid in the treatment of severe ovarian hyperstimulation syndrome. Fertil Steril 58: 1056 - 1059, 1992

    PubMed  CAS  Google Scholar 

  49. Fukaya T, Chida S, Terada Y, Funayama Y, Yajima A. Treatment of severe ovarian hyperstimulation syndrome by ultrafiltration and reinfusion of ascitic fluid. Fertil Steril 61: 561 - 564, 1994

    PubMed  CAS  Google Scholar 

  50. Physician Desk Reference 40th edition. INDOCIN 1187, 1986

    Google Scholar 

  51. Katz Z, Lancet M, Borenstein R, Chemke J. Absence of teratogenicity of Indomethacin in ovarian hyperstimulation syndrome. Int J Fertil 29: 186, 1984

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. V. Insler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Lunenfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Lunenfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Gynecology and Reproductive Medicine, University Women’s Hospital, Voßstrasse 9, 69115, Heidelberg, Germany

    Thomas Rabe (Prof. Dr. med. Dr. h.c.) & Benno Runnebaum (Prof. Dr. med. Dr. h.c.) (Prof. Dr. med. Dr. h.c.) &  (Prof. Dr. med. Dr. h.c.)

  2. Department of Obstetrics and Gynecology, Medical University Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany

    Klaus Diedrich (Prof. Dr. med.) (Prof. Dr. med.)

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Insler, V., Lunenfeld, E., Lunenfeld, B. (1997). Ovarian Hyperstimulation Syndrome. In: Rabe, T., Diedrich, K., Runnebaum, B. (eds) Manual on Assisted Reproduction. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-00763-1_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-00763-1_6

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-00765-5

  • Online ISBN: 978-3-662-00763-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation